|4Nov 14, 4:06 PM ET

CELGENE CORP /DE/ 4

4 · AGIOS PHARMACEUTICALS, INC. · Filed Nov 14, 2019

Insider Transaction Report

Form 4
Period: 2019-11-12
Transactions
  • Purchase

    Common Stock

    2019-11-12$31.00/sh+403,225$12,499,9751,777,824 total
Holdings
  • Common Stock

    (indirect: See footnote)
    624,575
  • Common Stock

    (indirect: See footnote)
    708,333
  • Common Stock

    (indirect: See footnote)
    4,010,926
Footnotes (3)
  • [F1]Owned directly by Celgene Switzerland LLC, a wholly-owned subsidiary of Celgene Corporation ("Celgene"). Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
  • [F2]Owned directly by Celgene European Investment Company LLC, a wholly-owned subsidiary of Celgene. Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
  • [F3]Owned directly by Celgene Alpine Investment Co., LLC, a wholly-owned subsidiary of Celgene. Celgene and the other reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Documents

1 file
  • 4
    tm1922788d1_4.xmlPrimary

    FORM 4